Lipocine (NASDAQ:LPCN) Director Buys $27,131.76 in Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 12,561 shares of Lipocine stock in a transaction on Monday, September 28th. The stock was acquired at an average cost of $2.16 per share, with a total value of $27,131.76. Following the acquisition, the director owned 216,358 shares of the company’s stock, valued at $467,333.28. This trade represents a 6.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lipocine Stock Performance

Shares of NASDAQ LPCN opened at $2.05 on Friday. Lipocine Inc. has a one year low of $1.81 and a one year high of $12.37. The firm has a market capitalization of $16.89 million, a P/E ratio of -1.15 and a beta of 0.40. The company’s fifty day moving average is $2.17 and its two-hundred day moving average is $2.73.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. The business had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. On average, sell-side analysts forecast that Lipocine Inc. will post -1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

LPCN has been the topic of several recent research reports. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Lipocine in a research note on Monday, September 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a report on Tuesday, September 22nd. Finally, Weiss Ratings raised Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.00.

Institutional Trading of Lipocine

Hedge funds have recently bought and sold shares of the company. Eversept Partners LP purchased a new stake in Lipocine in the 1st quarter worth approximately $2,357,000. AIGH Capital Management LLC purchased a new position in shares of Lipocine during the 1st quarter worth $1,598,000. Stempoint Capital LP purchased a new position in shares of Lipocine during the 1st quarter worth $1,282,000. Seven Fleet Capital Management LP acquired a new stake in shares of Lipocine during the first quarter worth $998,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Lipocine during the fourth quarter worth $567,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.